For instance, a clinical trial for BL‐8040, a CXCR4 inhibitor, in combination with immune checkpoint inhibition, showed improved CTL tumour infiltration, decreased immunosuppressive immune cells, and improved overall PDAC patient survival [17]. The gene discussed is CXCR4; the disease is neoplasm.